Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 28;13(24):2896-2910.
doi: 10.1016/j.jcin.2020.08.038.

Superior Vena Cava Syndrome

Abdul Hussain Azizi  1 , Irfan Shafi  2 , Neal Shah  1 , Kenneth Rosenfield  3 , Robert Schainfeld  3 , Akhilesh Sista  4 , Riyaz Bashir  5
Affiliations
Free article
Review

Superior Vena Cava Syndrome

Abdul Hussain Azizi et al. JACC Cardiovasc Interv. .
Free article

Abstract

Superior vena cava (SVC) syndrome comprises a constellation of clinical signs and symptoms caused by obstruction of blood flow through the SVC. The management of patients with life-threatening SVC syndrome is evolving from radiation therapy to endovascular therapy as the first-line treatment. There is a paucity of data and societal guidelines with regard to the management of SVC syndrome. This paper aims to update the practicing interventionalists with the contemporary and the evolving therapeutic approach to SVC syndrome. In addition, the review will focus on endovascular techniques, including catheter-directed thrombolysis, angioplasty, and stenting, and their associated complications.

Keywords: catheter-directed thrombolysis; endovascular therapy; superior vena cava obstruction.

PubMed Disclaimer

Conflict of interest statement

Author Disclosures Dr. Rosenfield has served as a consultant for Abbott, Access Vascular, Accolade, Capture Vascular, Endospan, Magneto, Micell, Shockwave, Silk Road, Surmodics, Thrombolex, and Valcare; owns equity interest in Access Vascular, Contego, Embolitech, Eximo, MD Insider, Janacare, PQ Bypass, and Primacea; and has received research or fellowship support from National Institutes of Health. Dr. Bashir owns equity interest in Thrombolex Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

LinkOut - more resources